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We sought to validate an in vitro system which could predict the minimal effect dose of antiretroviral agents.
Mixtures of uninfected CEM cells and CEM cells chronically infected with human immunodeficiency virus
(HIV) type 1 MN were exposed to 2',3'-didehydro-3'-deoxythymidine (D4T) in vitro in a hollow-fiber model
which simulates the plasma concentration-time profile of D4T in patients. Drug concentration was adjusted to
simulate continuous intravenous infusion, or an intravenous bolus administered twice daily. The effect of the
dosing regimen was measured with viral infectivity, p24 antigen, and reverse transcriptase or PCR for
unintegrated HIV DNA. Dose deescalation studies on a twice-daily dosing schedule predicted a minimum effect
dose of 0.5 mg/kg of body weight per day which correlated with the results of a clinical trial. Antiviral effect was
demonstrated to be independent of schedule for every 12-h dosing versus continuous infusion. Finally, at or
near the minimal effect dose, efficacy appeared to depend on the viral load. The ability of this in vitro
pharmacodynamic model to assess the response of HIV-infected cells to different doses and schedules of
antiviral agents may be useful in the design of optimal dosing regimens for clinical trials but requires
validation with other types of antiretroviral agents.

109 cells per unit as documented in preliminary experiments
performed with CEM and other lymphoid cells (2).

In vitro models have been used to evaluate the pharmacodynamics of antibacterial and anticancer agents for nearly two
decades. Several types of in vitro systems have been developed
in which cells or bacterial pathogens are grown in a suitable
medium and exposed to fluctuating concentrations of drugs
which are adjusted to mimic concentrations in serum obtained
in humans following single or multiple doses. The results of
studies with antibacterial compounds alone or in combination
have been consistent with observations in established animal
models of infection and have proven useful in the design of
subsequent clinical investigations (3, 6, 7, 9).
Hollow-fiber (HF) bioreactors (13) have been used to
cultivate hybridomas and other animal and human cell types.
These systems have also been employed to grow human
immunodeficiency virus (HIV) to high density and to harvest
p24 antigen (10). We have developed a perfusion system in
which either HIV-infected or uninfected human T-cell lines
can be propagated in the extracapillary chamber of multiple
HF bioreactor units. Nutrients are continuously pumped
through this system to support growth of HIV-infected cells;
antiviral agents can be added and removed at a rate which
simulates human pharmacokinetic patterns for the agent. In
these studies, we have used this system to analyze drug
exposure-efficacy relationships for the nucleoside antiretroviral
agent D4T (2',3'-didehydro-3'-deoxythymidine). This system
permits continuous cell growth to densities of 2 x 109 to 3 x

MATERIALS AND METHODS
Cells and viruses. The human T-lymphoblastoid cell line
CEM and the H9 cell line infected with HIV type 1 (HIV-1)
strain MN (HIV-IMN) (H9/HTLV-IIIMN NIH 1984) were
obtained from the AIDS Research and Reference Reagent
Program, AIDS Program, National Institute of Allergy and
Infectious Diseases, Bethesda, Md. CEM cells adapted to
growth in HF bioreactors were infected with cell-free supernatant from HIV-1MN-infected H9 cells, and a CEM cell line
which continuously produced HIV-1MN (CEM-MN) was established. All cell lines do not require exogenous interleukin 2
and were cultivated in RPMI 1640 medium with 25 mM HEPES
(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer
(90%) and 10% fetal calf serum (Paragon, Baltimore, Md.).
The percentage of infected cells was determined by flow
cytometry with the anti-p24 monoclonal antibody KC-57 as
previously described (14). Reverse transcriptase activity present
in cell-free supernatants from HF cultures was determined as
described by M. Popovic et al. (18).
In vitro pharmacokinetic model system. A schematic diagram of our perfusion system which utilizes commercially
available HF bioreactor units is shown in Fig. 1. Human
T-lymphocyte cell lines were propagated on and surrounding a
network of HF artificial capillaries enclosed within the extracapillary chamber of a plastic bioreactor cartridge (Mini-B
cellulose, 10,000-Da mean pore size; Cellco Inc., Germantown,
Md.). Experiments to monitor virus spread were initiated with
107 CEM cells and 104 CEM-MN cells (1:1,000 infected/
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FIG. 1. Schematic diagram of the in vitro pharmacodynamic model system. One of the two systems enclosed within a single incubator housed
in a biological safety cabinet is shown. Cells are grown, and samples are removed from the extracapillary compartment of HF bioreactors. Constant
infusion, oral, or intravenous bolus doses are introduced through the dosing ports in the diluent reservoir, absorption compartment, or central
reservoir, respectively. Exposure of cells to fluctuating concentrations of D4T is affected by programmed dilution of drug within the central
reservoir, while the volume of the central compartment is maintained as a constant by elimination. The mean pore diameter of the HF capillaries
(10 kDa) would prevent HIV or HIV-infected cells from exiting the bioreactor and from circulating through the tubing. (Further information is
available upon request.)

uninfected cell [i/u] ratio). In some experiments, bioreactors
were started at a 1:100 i/u ratio (10 CEM cells and 105
CEM-MN cells). The system was perfused with modified
RPMI 1640 medium with 25 mM HEPES buffer and 50 ,ug of
gentamicin per ml (90%; Paragon Biotech), 10% fetal calf
serum, and Nutridotna-Hu (Boehringer, Indianapolis, Ind.).
Glucose utilization was monitored with glucose test strips, and
the percentage of viable cells was measured with trypan blue
exclusion. D4T was added to either the diluent reservoir
(continuous infusion) or the central reservoir (intravenous
bolus). Details of the simulation of human plasma pharmacokinetics of antiviral agents and biological response modifiers by
programmed dilution of drug introduced into the central
reservoir will be published elsewhere (la). Plasma D4T concentrations simulated in the model were based on published
pharmacokinetic parameters from patients (8). The diluent
pump rate (i.e., the system clearance) was determined from the

product of the desired elimination rate constant (based on a
1-h half-life) and the total volume of the in vitro model system
(100 ml). Drug doses for the model were calculated to yield the
same peak and area under the curve values that would be
obtained in vivo for a 70-kg human receiving the milligram per
kilogram of body weight dose level tested.
ELISA for HIV p24. Aliquots of cells and tissue culture
media were removed through the extracapillary access ports on
the bioreactors at the indicated time points and centrifuged for
5 min at 1,500 x g. HIV gag p24 protein in cell-free culture
supernatants was measured by the Coulter p24 enzyme-linked
immunosorbent assay (ELISA) according to the manufacturer's guidelines (Coulter Immunology, Hialeah, Fla.). Absorbance was measured and data were analyzed with a computersupported microplate reader (Molecular Devices, Menlo Park,
Calif.). Baseline (day 0, time zero) p24 was subtracted from
values obtained on later days. Mean ± standard deviation of

Downloaded from http://aac.asm.org/ on August 21, 2018 by guest

(V

Elimination Reservoir

1387

1388

BILELLO ET AL.

ANTIMICROB. AGENTS CHEMOTHER.

TABLE 1. Effect of D4T on the spread of HIV-lMNa
No. of
Treatment

Treatmnt

i/uRatio'
i/u Ratiob

unintegrated
activity
HIV copies RT'
(cpm/10 RI)
per pg of

p24

(pg/mi)

E

DNA

< 100
<100
145,000
22,000
<100
<100

57,175
1,142
75,200
19,100
10,750
9,240

120,500
Not done

87,000
19,000
<100
<100

49,200
11,700
Not done
Not done

123,000
20,300
14,800
3,000

102,000
47,600
6,730
1,590

a Comparison of the efficacy of 1 mg of D4T per kg/day administered as a
constant infusion and as 0.5 mg/kg twice daily. Mixtures of CEM cells chronically
infected with HIV-lMN (CEM-MN) and uninfected CEM cells were grown in HF
bioreactors. Cells were exposed to D4T either as a constant infusion or as a
twice-daily dose administered as a simulated intravenous bolus with levels of
D4T in the HF bioreactor mimicking typical human serum pharmacokinetics. At
day 9, samples of cells and tissue culture fluid from the extracapillary space were
taken at a trough point for the analysis of HIV-1 DNA, p24, and reverse

transcriptase activity.
b The initial ratio of CEM-MN cells to uninfected CEM cells used to initiate
HF bioreactors.
c RT, reverse transcriptase.

duplicate samples was used for calculation of p24 level. The
coefficient of variation is approximately 5% for p24 assays
performed on different days.
Unintegrated DNA assay. Samples of 1 x 106 to 3 x 106 cells
were used for isolation of high- and low-molecular-weight
DNA with an extraction procedure modified from that described by Hirt (11). Cells from bioreactors with extensive
unintegrated HIV DNA synthesis were often diluted 10- and
100-fold in uninfected CEM cells prior to Hirt DNA preparation. Hot-start PCR was performed with the SK38/39 gag
primers and probe (SK19) for the HIV-1 gag region with
reagents from and conditions recommended by Perkin-Elmer
Cetus (Norwalk, Conn.). Amplification products were analyzed
on 1% NuSieve agarose gels, transferred to nitrocellulose
(BIOS, New Haven, Conn.), and fixed by exposure to UV. The
blots were hybridized with an SK19 probe labeled with digoxigenin-dUTP by using terminal deoxynucleotide transferase.
Hybridization conditions and detection with antidigoxigenin
Fab fragments conjugated with alkaline phosphatase (Genius
System; Boehringer Mannheim) were according to manufacturer's instructions. The numbers of copies of HIV proviral
DNA detectable in high- and low-molecular-weight DNA
preparations were estimated by extrapolation to a standard
curve performed with known copy numbers of HIV-1 plasmid
DNA.

RESULTS
Inhibition of HIV replication by continuous infusion of D4T.
By initiating a series of HF bioreactors with a mixture of
infected and uninfected cells, we have shown the ability of D4T
(a pyrimidine analog and inhibitor of reverse transcriptase) to
prevent the spread of HIV-lMN to uninfected CEM cells in
continuous-infusion regimens. Table 1 shows that D4T, when
administered as a simulated continuous intravenous infusion of
a dose of 1 mg/kg/day, inhibited the spread of HIV to
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FIG. 2. Simulated plasma concentration curve for D4T (1 mg/kg/
day) given as a continuous infusion or divided into two doses administered at 12-h intervals. The elimination half-life of D4T was set
according to human studies (8).

uninfected cells. Inhibition of de novo replication was demonstrable by measurement of reverse transcriptase or p24 in the
cell-free media or by quantitative analysis of integrated and
unintegrated species of HIV-1 DNA by PCR. High levels of
unintegrated DNA are associated with active HIV DNA
synthesis (12, 17). The lower copy numbers of unintegrated
HIV DNA in D4T-treated HF cultures, relative to untreated
controls, are similar to the decrease in unintegrated HIV DNA
in lymphocytes from AIDS patients after initiation of antiretroviral therapy (5).
In vitro simulation of human pharmacokinetics. The same
two-compartment in vitro system was used to simulate both
continuous infusion and an intravenous bolus of the antiviral
agent. In experiments in which drug was removed from the
central compartment at a rate simulating the pharmacokinetic
pattern of D4T (5), the 1-mg/kg/day D4T dose was studied in
an every-12-h dosing schedule (Fig. 2). Figure 3a depicts the
effect of D4T at a dose of 0.5 mg/kg administered at 12-h
intervals. The daily levels of p24 antigen in the HF units
inoculated with HIV-1MN-infected CEM cells at 1:1,000 and
1:100 i/u ratios are shown. While p24 levels increased in the
untreated bioreactor culture (open squares), there was a
constant level of release of viral p24 into the extracapillary
chamber of bioreactors exposed to D4T on a twice-daily (BID)
schedule. This constant level of p24 expression represents virus
release from the chronically infected cells which were used to
initiate infection of the bioreactors. Analysis of HIV-1 DNA
showed that the numbers of unintegrated copies of HIV-1
DNA increased markedly over a 7-day interval in untreated
HF units (Fig. 3b). In marked contrast, <100 copies of
unintegrated HIV DNA were amplified from D4T-treated
cultures, indicative of effective viral suppression by the dose
employed (Table 1). Flow cytometric analysis of the number
of cells expressing intracellular p24 indicated that D4T inhibited cell-to-cell spread of HIV since the percentage of
infected cells in the D4T-exposed cultures approximated the
input i/u ratio, while untreated cultures had >70% p24positive cells.
In vitro dose deescalation studies. Figure 4a depicts the
effect of a dose deescalation to 0.5 mg/kg/day administered on
a every-12-h schedule. As was seen previously, the level of p24
gradually increased in the non-drug-exposed chambers inoculated with HIV-IMN-infected cells at a ratio of 1:1,000 (open
squares). Viral infection of previously uninfected cells was
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Constant infusion
None
CEM-MN
None
CEM
None
1:100
None
1:1,000
1 mg/kg/day
1:100
1 mg/kg/day
1:1,000
Bolus
None
1:100
None
1:1,000
0.5 mg/kg/BID 1:100
0.5 mg/kg/BID 1:1,000
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a

demonstrated by increased p24 antigen production at day 8 in
the D4T-exposed cultures with an i/u ratio of 1:100. This was
not apparent for the unit challenged with a ratio of 1:1,000 i/u
cells. However, PCR analysis of cells from the 1:1,000 i/u
D4T-treated culture showed an increase from <100 (on day 1)
to approximately 600 copies of unintegrated DNA per,Lg on
day 10, which suggests a low level of de novo infection of this
culture on the 0.25-mg/kg BID regimen. Figure 4b indicates
that decreasing the D4T dose to 0.25 mg/kg/day (0.125 mg/kg
every 12 h) resulted in levels of viral replication comparable to
those of untreated cultures.
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lengthy

bols: O, no treatment (1:1,000 i/u); O, D4T (1:100 i/u); *, D4T
(1:1,000 i/u). (b) PCR was performed on high- and low-molecularweight fractions of DNA from CEM cells cocultivated with 1:100 or

1:1,000

deescalation studies in cllnc.

CEM-MN cells. Cells in the bioreactors were either untreated

or exposed to
no treatment;

D4T at 0.5 mg/kg, BID. p.i., postinfection. Symbols:
D4T (1:1,000 i/u).
0, D4T (1:100 i/u);
5,

1,
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There were three important findings in our study. The first is
that we were able to identify the minimal effect dose of D4T.
5
The phase I study reported by Browne et al. (4) started at 4
mg/kg/day, and the dose was escalated until a daily dose of
*__
-----12 mg/kg/day was reached. Little extra antiretroviral activ_
ity was gained during this dose escalation, but greatly in:___,___,___,___,___,___,___.___.___.
0
creased drug toxicity became manifest. On an every-12-h
0 1 2 3 4 5 6 7 8 9 10
dosing schedule, activity was maintained and toxicity was
lessened at doses down to 0.5 mg/kg/day. Suboptimal antiviral
These
were evident at doses of 0.25 mg/kg/day
effects
(1). of
p.i.
Days
the findings
our
Days
clinical findings are in excellent accord with
in vitro system. It is obvious that a great deal of time in the
b
drug development process can be saved if minimal effect
starting doses of antiretroviral agents can be identified before
the start of phase I/II investigations. Further, the lack of effect
of administration schedule (at least between continuous infu....sion and BID administration) on antiviral endpoints was
20
demonstrated.
0
We were also able to demonstrate that the drug effect was,
Iat least to a degree, dependent on the viral load (the absolute
....challenge to the system). Viral breakthrough occurred one
.....
z 15
dose deescalation step earlier with the higher (1:100 i/u ratio)
a
challenge. This is a finding which requires clinical correlacm
tions. Our ability to demonstrate this in vitro may have been
related to the absolute numbers of cells and consequent
..................................... .... ....
0 10
number of rounds of viral replication that we were able to
achieve (the numbers of cells in the HF bioreactors ap0
proached 3 x 109).
While other cell types and strains of HIV can be used, this
|
._
used CEM cells chronically infected with
to
study
examine the antiviral effect of D4T. These cells were cocultivated with uninfected CEM cells at ratios of 1:100 and 1:1,000
z
_________________________
0m
EL
These ratios were chosen to represent a formidable
I
I
~~~~~~~~challenge 10- to 100-fold above the percentage of HIVinfected CD4+ cells in the lymphoid organs of infected pa3
4
5
6
7
2
1
tients (15, 16). Practically, they were also chosen since the
results were readily evaluable at the 1:1,000 ratio within 2
Days piI
weeks under standard conditions in the HF culture unit. In
addition, HIV-1MN was chosen because its 50% effective dose
FIG. 3. (a Effect of D4T (0.5 mg/kg, BID) on the spread of
for D4T is in the middle of the range for isolates likely to be
bioreactors were set with 107 CEM cells and 104
HIV-lMN. Tmllswo (1:1,000
i/u ratio). A third bioreactor was started at a
encountered clinically.
CEM-MN cel
In summary, the in vitro HF system study of D4T pharma1:100 i/u ratic:. A 1:100 and a 1:1,000 bioreactor were exposed to D4T
and the pharmacokinetics of D4T was
codynamics using simulated human pharmacokinetics pre(0.5 mg/kg) ait 12-h intervals,
dicted the minimal effect
dose. obtained
after extensive.. and
simulated by dilution of the circulating drug. Postdistributional peak
.
.
concentrationis were set at 0.5092 ,ug/ml (2.27 ,uM). D4T levels were
sueitecn.
below the linrnit of detection 3 to 4 h after dosing. The D4T-treated
The minimal
the
dosewas shown to be approximately
0.5 mg/kg/day
effect dose
bioreactors were set in parallel while the untreated unit was continuously exposed to medium without drug. Samples were taken at trough
points 12 h after dosing, and p24 was measured as indicated. The
results shown are from a single experiment. p.i., postinfection. Sym-
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administered on an every-12-h schedule either in the HF
system or in the clinic. This finding suggests that in vitro HF
pharmacodynamic modeling may be an extremely useful tool in
the preclinical evaluation process.
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